Bayer’s Kerendia (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
RegulatoryapprovedKerendiaPositive
AI Analysis
Summary
Bayer announced FDA approval of Kerendia (finerenone) for adults with chronic kidney disease and Type 1 Diabetes, marking the first new treatment for this indication in 30 years. The approval is based on the drug's ability to reduce urinary albumin-to-creatinine ratio.
Outcome Details
FDA approved Kerendia (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with CKD and Type 1 Diabetes; first new treatment in 30 years for this indication
Importance:9/10
Sentiment:
0.95
FDA approvalCKDType 1 Diabetesfirst-in-classrare disease
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 17, 2026 8:09 PM